Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bought it.
It's a win-win either way.
I have been wondering if the current share price rise relates to a private placement to raise cash somewhat duplicating the 2010 transactions.
History does repeat itself.
If that's it, I will be as excited as I was the last time. If it's something else related to the progress of stuff in the pipeline, I'll be excited about that too.
Agreed, the dividend is impressive with little downside risk on top of that.
I am looking forward to seeing the results tonight.
Star Bulk Announces Date for the Release of Fourth Quarter and Year End 2011 Results, Conference Call and Webcast
ATHENS, GREECE -- (Marketwire) -- 02/01/12 -- Star Bulk Carriers Corp. (the "Company" or "Star Bulk") (NASDAQ: SBLK) today announced that it will release its results for the fourth quarter and year end 2011 after the market closes in New York on Wednesday, February 15, 2012.
Star Bulk's management team will host a conference call to discuss the Company's financial results on Thursday, February 16, 2012, at 8:30 a.m. Eastern Standard Time (EST).
Lots of volume but there is little steam driving it upwards. Maybe there are profit takers cashing out after buying in last month in the .80's and low .90's, but there are plenty of buyers.
Hopefully the news is going to be good.
Upcoming Events
Date/Time Type Details
Feb 16, 2012 / 8:30AM Conference Call Star Bulk Carriers
At no time in the last 3 years other than July 19th has SBLK traded more heavily than it is trading today.
It does seem like AEN is caught in a rip tide today.
A few of the talking heads on CNBC last week mentioned dry bulk shipping as a better place to put money, than tanker companies.
There are several dry shippers moving up today against the tide.
You may be right about the earnings coming out being a stimulant, but I think SBLK may be benefiting from it's low investment price, limited downside, and hefty dividend yield.
AEN is presenting at the very prestigious Harvard Investors Group tonight. A lot of good should come from this. Companies have to be invited to make presentations.
Harvard Investors Group to host a dinner meeting
Dinner Meeting where featured presenter, Jeff Riley, CEO of Adeona Pharmaceuticals provides an overview of the Company's synthetic biologics program, its collaboration with Intrexon Corporation for pulmonary arterial hypertension and its funded clinical trial programs is being held in New York on February 13.
AEN is presenting at the very prestigious Harvard Investors Group tonight. A lot of good should come from this. Companies have to be invited to make presentations.
Harvard Investors Group to host a dinner meeting
Dinner Meeting where featured presenter, Jeff Riley, CEO of Adeona Pharmaceuticals provides an overview of the Company's synthetic biologics program, its collaboration with Intrexon Corporation for pulmonary arterial hypertension and its funded clinical trial programs is being held in New York on February 13.
A lot of good should come from this. It's a very prestigious forum. Companies have to be invited to make presentations.
Harvard Investors Group to host a dinner meeting
Dinner Meeting where featured presenter, Jeff Riley, CEO of Adeona Pharmaceuticals provides an overview of the Company's synthetic biologics program, its collaboration with Intrexon Corporation for pulmonary arterial hypertension and its funded clinical trial programs is being held in New York on February 13.
Their chart looks terrific.
Still, it's odd how much time has passed since the RS, without the price sinking as it did almost immediately after the prior RS's.
It's tough to ignore history repeating itself, but for the time being, things are different.
It appears after all these years, we may own the "newest" hot company that's getting ready to break out with a "hit" product.
wouldn't that be exciting!
Bashers ... we never had one.
Presenting at a Harvard investor conference, not diluting the stock, every trial advancing to the next phase, getting private and public agency grants, and a terrific board of director resume portfolio makes AEN a terrific bet.
I am very surprised the price hasn't started to bottom out just like after the previous RS's. It almost made a straight line to sub penny each time.
This might actually be the time they don't dilute the heck out of the stock and it actually can trade without a printing press to dilute the share value.
Cabo may really have been the stabalizing answer they needed.
Then again that might be complete BS.
kezzek Share Friday, February 10, 2012 12:43:42 PM
Re: griff100 post# 66643 Tweet Post # of 66650
I doubt it will take 6 months to get to a dime, though it could be like LIQR and just stop trading any volume.
Now that insiders own 89% and got most of it for free, I expect they'll be happy with whatever they can get.
Institutions are buying into AEN. Check out the list at the bottom of this post.
It should only get better after this.
Adeona CEO to Present at the Harvard Investors Group Forum
PR Newswire Posted 3:33 PM 02/09/12
ANN ARBOR, Mich., Feb. 9, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that Jeff Riley, the Company's Chief Executive Officer and Chairman, will be the featured presenter at the upcoming Harvard Investors Group forum. Mr. Riley will provide an overview of the Company's synthetic biologics program, its collaboration with Intrexon Corporation for pulmonary arterial hypertension and its funded clinical trial programs at the invitation-only dinner event on Monday evening, February 13, 2012, at The Manhattan Club in New York City.
"Our group of qualified investors and investment professionals within the New York City financial and investment industries is pleased to welcome Mr. Riley to the upcoming Harvard Investors Group dinner meeting," said John O'Dea, Chairman of the Harvard Investors Group. "Adeona's new senior management team will provide our invited guests with an in-depth look at the Company's new focus on the emerging area of synthetic DNA-based therapeutics, as well as its funded clinical programs for multiple sclerosis, fibromyalgia and ALS."
Adeona intends to file the slide deck used at the Harvard Investors Group forum in a Current Report on Form 8-K with the Securities & Exchange Commission, concurrent with its presentation on Monday, February 13, 2102.
About Harvard Investors Group
Harvard Investors Group is a private organization. Attendance is by invitation only. Harvard Investors Group provides a forum for public and private companies to present information about their businesses to securities industry professionals. Harvard Investors Group neither recommends nor solicits participation in the presenting companies. Harvard Investors Group receives a fee for arranging each of its meetings. Harvard Investors Group and the meetings it hosts are in no way affiliated with Harvard University. No business solicitations of presenting companies are permitted at the meetings. For more information about Harvard Investors Group, please visit the website at www.harvardinvestors.org.
About Adeona Pharmaceuticals, Inc.
Adeona is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Adeona is developing, or has partnered the development of, product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis (ALS). For more information, please visit Adeona's website at www.adeonapharma.com.
Adeona is currently d/b/a Synthetic Biologics, Inc. (NYSE Amex: SYN) pending stockholder approval of the name change at a Special Meeting to be held on February 15, 2012. The proposed name change better reflects the Company's mission and primary business focus on the emerging field of synthetic biologics.
Synthetic Biologics is a trademark of Adeona Pharmaceuticals, Inc.
SOURCE Adeona Pharmaceuticals, Inc
Adeona Pharmaceuticals, Inc. Co (AEN)
-AMEX
2.70 Up 0.17(6.72%) 4:00PM EST
Add to Portfolio
Major Holders Get Major Holders for:
Breakdown
% of Shares Held by All Insider and 5% Owners: 52%
% of Shares Held by Institutional & Mutual Fund Owners: 2%
% of Float Held by Institutional & Mutual Fund Owners: 3%
Number of Institutions Holding Shares: 9
Major Direct Holders (Forms 3 & 4)
Holder Shares Reported
KUO JAMES S 4,500 Aug 30, 2011
Top Institutional Holders
Holder Shares % Out Value* Reported
VANGUARD GROUP, INC. (THE) 177,478 0.57 104,712 Sep 30, 2011
CALPERS (CALIFORNIA-PUBLIC EMPLOYEES RETIREMENT SYSTEM) 100,350 0.32 59,206 Sep 30, 2011
GEODE CAPITAL MANAGEMENT, LLC 61,943 0.20 36,546 Sep 30, 2011
MORGAN STANLEY 24,472 0.08 14,438 Sep 30, 2011
SHOTT CAPITAL MANAGEMENT, LLC 23,855 0.08 30,057 Dec 31, 2011
UBS AG 17,575 0.06 10,369 Sep 30, 2011
DIMENSIONAL FUND ADVISORS LP 15,400 0.05 9,086 Sep 30, 2011
Bard Associates Inc. 13,399 0.04 7,905 Sep 30, 2011
WELLS FARGO & COMPANY 700 0.00 413 Sep 30, 2011
Top Mutual Fund Holders
Holder Shares % Out Value* Reported
VANGUARD EXTENDED MARKET INDEX FUND 177,478 0.57 104,712 Sep 30, 2011
SPARTAN EXTENDED MARKET INDEX FUND 51,943 0.17 49,865 Nov 30, 2011
DFA U.S. SMALL CAP SERIES 9,451 0.03 7,749 Jul 31, 2011
SPARTAN TOTAL MARKET INDEX FUND 9,114 0.03 8,749 Nov 30, 2011
View Transactions for Insiders & Institutional Holders
Value shown is computed using the security's price on the report date given.
Currency in USD.
Institutions are buying into AEN. Check out the list at the bottom of this post.
It should only get better after this.
Adeona CEO to Present at the Harvard Investors Group Forum
PR Newswire Posted 3:33 PM 02/09/12
ANN ARBOR, Mich., Feb. 9, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that Jeff Riley, the Company's Chief Executive Officer and Chairman, will be the featured presenter at the upcoming Harvard Investors Group forum. Mr. Riley will provide an overview of the Company's synthetic biologics program, its collaboration with Intrexon Corporation for pulmonary arterial hypertension and its funded clinical trial programs at the invitation-only dinner event on Monday evening, February 13, 2012, at The Manhattan Club in New York City.
"Our group of qualified investors and investment professionals within the New York City financial and investment industries is pleased to welcome Mr. Riley to the upcoming Harvard Investors Group dinner meeting," said John O'Dea, Chairman of the Harvard Investors Group. "Adeona's new senior management team will provide our invited guests with an in-depth look at the Company's new focus on the emerging area of synthetic DNA-based therapeutics, as well as its funded clinical programs for multiple sclerosis, fibromyalgia and ALS."
Adeona intends to file the slide deck used at the Harvard Investors Group forum in a Current Report on Form 8-K with the Securities & Exchange Commission, concurrent with its presentation on Monday, February 13, 2102.
About Harvard Investors Group
Harvard Investors Group is a private organization. Attendance is by invitation only. Harvard Investors Group provides a forum for public and private companies to present information about their businesses to securities industry professionals. Harvard Investors Group neither recommends nor solicits participation in the presenting companies. Harvard Investors Group receives a fee for arranging each of its meetings. Harvard Investors Group and the meetings it hosts are in no way affiliated with Harvard University. No business solicitations of presenting companies are permitted at the meetings. For more information about Harvard Investors Group, please visit the website at www.harvardinvestors.org.
About Adeona Pharmaceuticals, Inc.
Adeona is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Adeona is developing, or has partnered the development of, product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis (ALS). For more information, please visit Adeona's website at www.adeonapharma.com.
Adeona is currently d/b/a Synthetic Biologics, Inc. (NYSE Amex: SYN) pending stockholder approval of the name change at a Special Meeting to be held on February 15, 2012. The proposed name change better reflects the Company's mission and primary business focus on the emerging field of synthetic biologics.
Synthetic Biologics is a trademark of Adeona Pharmaceuticals, Inc.
SOURCE Adeona Pharmaceuticals, Inc
Adeona Pharmaceuticals, Inc. Co (AEN)
-AMEX
2.70 Up 0.17(6.72%) 4:00PM EST
Add to Portfolio
Major Holders Get Major Holders for:
Breakdown
% of Shares Held by All Insider and 5% Owners: 52%
% of Shares Held by Institutional & Mutual Fund Owners: 2%
% of Float Held by Institutional & Mutual Fund Owners: 3%
Number of Institutions Holding Shares: 9
Major Direct Holders (Forms 3 & 4)
Holder Shares Reported
KUO JAMES S 4,500 Aug 30, 2011
Top Institutional Holders
Holder Shares % Out Value* Reported
VANGUARD GROUP, INC. (THE) 177,478 0.57 104,712 Sep 30, 2011
CALPERS (CALIFORNIA-PUBLIC EMPLOYEES RETIREMENT SYSTEM) 100,350 0.32 59,206 Sep 30, 2011
GEODE CAPITAL MANAGEMENT, LLC 61,943 0.20 36,546 Sep 30, 2011
MORGAN STANLEY 24,472 0.08 14,438 Sep 30, 2011
SHOTT CAPITAL MANAGEMENT, LLC 23,855 0.08 30,057 Dec 31, 2011
UBS AG 17,575 0.06 10,369 Sep 30, 2011
DIMENSIONAL FUND ADVISORS LP 15,400 0.05 9,086 Sep 30, 2011
Bard Associates Inc. 13,399 0.04 7,905 Sep 30, 2011
WELLS FARGO & COMPANY 700 0.00 413 Sep 30, 2011
Top Mutual Fund Holders
Holder Shares % Out Value* Reported
VANGUARD EXTENDED MARKET INDEX FUND 177,478 0.57 104,712 Sep 30, 2011
SPARTAN EXTENDED MARKET INDEX FUND 51,943 0.17 49,865 Nov 30, 2011
DFA U.S. SMALL CAP SERIES 9,451 0.03 7,749 Jul 31, 2011
SPARTAN TOTAL MARKET INDEX FUND 9,114 0.03 8,749 Nov 30, 2011
View Transactions for Insiders & Institutional Holders
Value shown is computed using the security's price on the report date given.
Currency in USD.
Tremendouse news to see institutional investors getting involved in our little company. It should only get better after this.
Adeona CEO to Present at the Harvard Investors Group Forum
PR Newswire Posted 3:33 PM 02/09/12
ANN ARBOR, Mich., Feb. 9, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that Jeff Riley, the Company's Chief Executive Officer and Chairman, will be the featured presenter at the upcoming Harvard Investors Group forum. Mr. Riley will provide an overview of the Company's synthetic biologics program, its collaboration with Intrexon Corporation for pulmonary arterial hypertension and its funded clinical trial programs at the invitation-only dinner event on Monday evening, February 13, 2012, at The Manhattan Club in New York City.
"Our group of qualified investors and investment professionals within the New York City financial and investment industries is pleased to welcome Mr. Riley to the upcoming Harvard Investors Group dinner meeting," said John O'Dea, Chairman of the Harvard Investors Group. "Adeona's new senior management team will provide our invited guests with an in-depth look at the Company's new focus on the emerging area of synthetic DNA-based therapeutics, as well as its funded clinical programs for multiple sclerosis, fibromyalgia and ALS."
Adeona intends to file the slide deck used at the Harvard Investors Group forum in a Current Report on Form 8-K with the Securities & Exchange Commission, concurrent with its presentation on Monday, February 13, 2102.
About Harvard Investors Group
Harvard Investors Group is a private organization. Attendance is by invitation only. Harvard Investors Group provides a forum for public and private companies to present information about their businesses to securities industry professionals. Harvard Investors Group neither recommends nor solicits participation in the presenting companies. Harvard Investors Group receives a fee for arranging each of its meetings. Harvard Investors Group and the meetings it hosts are in no way affiliated with Harvard University. No business solicitations of presenting companies are permitted at the meetings. For more information about Harvard Investors Group, please visit the website at www.harvardinvestors.org.
About Adeona Pharmaceuticals, Inc.
Adeona is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Adeona is developing, or has partnered the development of, product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis (ALS). For more information, please visit Adeona's website at www.adeonapharma.com.
Adeona is currently d/b/a Synthetic Biologics, Inc. (NYSE Amex: SYN) pending stockholder approval of the name change at a Special Meeting to be held on February 15, 2012. The proposed name change better reflects the Company's mission and primary business focus on the emerging field of synthetic biologics.
Synthetic Biologics is a trademark of Adeona Pharmaceuticals, Inc.
SOURCE Adeona Pharmaceuticals, Inc
That's why I am also in an under the radar steady dividend payer of about 20% or 5¢ a quarter in the dry bulk shipping business.
Mind's revenue stream is pretty consistent. I don't know why they don't also pay quarterly.
Wow ... up 19¢ @ 3 p.m.
Just about 3 weeks to go until the dividend announcement.
It's likely we're watching a run-up to $3+ dollars or maybe it can top $3.40 just like before last year's payout.
It's a lot tougher to hook someone on a gamble at 70¢ than sub penny. At this level they have to show they can pay down debt, increase sales, and drive money to the bottom line.
They should have thought of that before they did the massive RS.
Yet I can't stop watching and checking in every once in a while.
I like how many small trades are being made. Lots of people are following AEN.
Your worry is needless ... I called the Sec of State office to find out what caused them to be in default.
The form actually says it, but 3 of us missed it.
They are in default for not filing a list of company officiers which was due on 12-31-2011. Nothing else is involved.
I asked if not filing the list was abnormal, or a relatively common occurance. I was told, "it's actually quite common".
Thanks for making us aware.
If anyone wants to ask the same questions and hear the answer for themselves the contact is:
Secretary of State
Nevada State Capitol Building
101 North Carson Street, Suite 3
Carson City, NV 89701
Phone: 775-684-5708 Choose Option "2"
50¢ to over $2.
$80 million more for Alzheimer's research.
This news has to be terrific for AEN which recently moved from 50¢ to over $2.
AEN virtually has no dilution.
Obama budget to include $80 million more for Alzheimer's research
By Noam N. Levey
8:52 AM PST, February 7, 2012
Reporting from Washington
With the president preparing to unveil his final budget proposal before the November election, the Obama administration announced plans Tuesday to dramatically boost funding for research into Alzheimer's disease.
Administration officials said the president would propose an additional $80 million in research funding next year, up from about $450 million this year.
The president will also call for another $26 million in funding to help support family and others who care for Americans suffering from the disease.
"This new funding will accelerate NIH efforts to use the power of science to develop new ways of helping people with Alzheimer's disease and those at risk," National Institutes of Health Director Dr. Francis S. Collins said.
Collins, who said NIH would dedicate another $50 million in existing research funding specifically for Alzheimer's research, said the push for more funding comes as scientific breakthroughs are offering researchers hope that meaningful treatments may be within reach.
Researchers, Collins said, are "poised for some great discoveries."
About 5 million Americans currently suffer from Alzheimer's, a degenerative form of dementia that primarily affects the elderly. But while the number of people with the disease is expected to grow dramatically as the population ages, there is currently no cure.
That has galvanized patient advocates, and in January 2011, Obama signed legislation calling for a national plan to combat the disease.
Tuesday's announcement was cheered by many advocates, who have been furiously pushing the administration and lawmakers on Capitol Hill to preserve research funding as pressure builds in Washington to slash federal spending.
"The administration's efforts to carve out funds for Alzheimer's disease despite the challenging fiscal environment signals its ongoing commitment to this devastating disease and helps pave the way for scientific discoveries that can potentially change lives and save lives," said Eric J. Hall, president and chief executive of the Alzheimer's Foundation of America.
noam.levey@latimes.com
$80 million more for Alzheimer's research.
This news has to be terrific for AEN which recently moved form 50¢ to over $2.
AEN virtually has no dilution.
Obama budget to include $80 million more for Alzheimer's research
By Noam N. Levey
8:52 AM PST, February 7, 2012
Reporting from Washington
With the president preparing to unveil his final budget proposal before the November election, the Obama administration announced plans Tuesday to dramatically boost funding for research into Alzheimer's disease.
Administration officials said the president would propose an additional $80 million in research funding next year, up from about $450 million this year.
The president will also call for another $26 million in funding to help support family and others who care for Americans suffering from the disease.
"This new funding will accelerate NIH efforts to use the power of science to develop new ways of helping people with Alzheimer's disease and those at risk," National Institutes of Health Director Dr. Francis S. Collins said.
Collins, who said NIH would dedicate another $50 million in existing research funding specifically for Alzheimer's research, said the push for more funding comes as scientific breakthroughs are offering researchers hope that meaningful treatments may be within reach.
Researchers, Collins said, are "poised for some great discoveries."
About 5 million Americans currently suffer from Alzheimer's, a degenerative form of dementia that primarily affects the elderly. But while the number of people with the disease is expected to grow dramatically as the population ages, there is currently no cure.
That has galvanized patient advocates, and in January 2011, Obama signed legislation calling for a national plan to combat the disease.
Tuesday's announcement was cheered by many advocates, who have been furiously pushing the administration and lawmakers on Capitol Hill to preserve research funding as pressure builds in Washington to slash federal spending.
"The administration's efforts to carve out funds for Alzheimer's disease despite the challenging fiscal environment signals its ongoing commitment to this devastating disease and helps pave the way for scientific discoveries that can potentially change lives and save lives," said Eric J. Hall, president and chief executive of the Alzheimer's Foundation of America.
noam.levey@latimes.com
This news has to be terrific for AEN.
Obama budget to include $80 million more for Alzheimer's research
By Noam N. Levey
8:52 AM PST, February 7, 2012
Reporting from Washington
With the president preparing to unveil his final budget proposal before the November election, the Obama administration announced plans Tuesday to dramatically boost funding for research into Alzheimer's disease.
Administration officials said the president would propose an additional $80 million in research funding next year, up from about $450 million this year.
The president will also call for another $26 million in funding to help support family and others who care for Americans suffering from the disease.
"This new funding will accelerate NIH efforts to use the power of science to develop new ways of helping people with Alzheimer's disease and those at risk," National Institutes of Health Director Dr. Francis S. Collins said.
Collins, who said NIH would dedicate another $50 million in existing research funding specifically for Alzheimer's research, said the push for more funding comes as scientific breakthroughs are offering researchers hope that meaningful treatments may be within reach.
Researchers, Collins said, are "poised for some great discoveries."
About 5 million Americans currently suffer from Alzheimer's, a degenerative form of dementia that primarily affects the elderly. But while the number of people with the disease is expected to grow dramatically as the population ages, there is currently no cure.
That has galvanized patient advocates, and in January 2011, Obama signed legislation calling for a national plan to combat the disease.
Tuesday's announcement was cheered by many advocates, who have been furiously pushing the administration and lawmakers on Capitol Hill to preserve research funding as pressure builds in Washington to slash federal spending.
"The administration's efforts to carve out funds for Alzheimer's disease despite the challenging fiscal environment signals its ongoing commitment to this devastating disease and helps pave the way for scientific discoveries that can potentially change lives and save lives," said Eric J. Hall, president and chief executive of the Alzheimer's Foundation of America.
noam.levey@latimes.com
I regret not buying more under a dollar. AEN is one of the most exciting potential stocks I have watched over the past 3 years. Every move is strategically thought out to advance the company. Every trial is advancing to the next stage. Even their raising of funds has been a mix between private investments, and government and foundation grants, with almost no dilution to speak of.
The best part is if AEN's drugs and therapies are successful, millions of people are going to benefit.
Waiting for another good reason to buy again. More regular progress reports would be nice; like how the US distributor market is coming along after VKNG made the last two marketing hires.
I am stunned that AEN didn't think it was news-worthy to put out a PR touting their mention in the Wall Street Journal.
Ann, Thanks for posting the link ...
A New Target in Fighting Brain Disease: Metals
By SHIRLEY S. WANG
Research into how iron, copper, zinc and other metals work in the brain may help unlock some of the secrets of degenerative diseases like Alzheimer's and Parkinson's.
One of the many theories explaining Alzheimer's disease is that some of the harm is caused by toxic metals accumulating in brain. Now a new study lends more credibility to the toxic metal theory. Shirley Wang has details on Lunch Break.
Iron and copper appear to accumulate beyond normal levels in the brains of people with these diseases, and a new, Australian study published Sunday shows reducing excess iron in the brain can alleviate Alzheimer's-like symptoms—at least in mice.
A genetic mutation related to regulating iron is linked to ALS, or Lou Gehrig's disease. Zinc, on the other hand, appears to impair memory if its levels get too low or if it gets into a brain region where it doesn't belong, as it can with traumatic brain injury.
Research into the complicated, invisible roles these metals play in brain diseases has lagged behind study of the more-visible proteins that are damaged or clump together in the brains of Alzheimer's and Parkinson's sufferers. But better understanding metals' role in the brain could help shed light on a range of medical conditions and might offer a new route for developing treatments, scientists say.
"The field is coming around to the idea of the cause of Alzheimer's being multifactorial," and disturbed metal regulation could be one of those factors, says Ralph Nixon, chairman of the Alzheimer Association's medical and scientific advisory council and director of the Silberstein Alzheimer's Institute at New York University.
Tiny metal ions—charged particles of the elements—serve several essential functions in the body, including facilitating chemical reactions to generate energy and preserving the structure of proteins. Strict checks and balances in a healthy body keep metal levels within a tight range.
But the biological changes that come with disease and aging—as opposed to poisoning from outside sources like food, supplements or metal pans—can knock levels of these metals out of whack in the brain.
Iron, for instance, is a "double-edged sword" because it interacts with oxygen to help the body generate energy, but also can produce free radicals, highly reactive molecules that can cause cell damage, says James Connor, professor and vice chairman of neurosurgery at Penn State University in Hershey.
If the body has too little iron, such as with anemia, the body doesn't generate enough energy to sustain important functions. But an overabundance of iron accumulated in the brain is toxic. Significantly higher accumulations of metal have been observed in the brains of people with Parkinson's and Alzheimer's disease than in healthy people of the same age, says Ashley Bush, a professor of pathology at the University of Melbourne.
The new study, conducted by Dr. Bush and colleagues and published in the journal Nature Medicine, examined the amount of iron in the brains of mice that were bred unable to produce the tau protein, which helps stabilize the structure of neurons. Tau damage is associated with Alzheimer's and Parkinson's.
As the mice aged, they suffered symptoms similar to people with both diseases, including impaired short-term memory, and also exhibited an accumulation of iron in their brains. When the researchers gave them a drug removing excess iron, the symptoms reversed. This means normally functioning tau is necessary for removing iron in the brain, Dr. Bush says. The finding bolsters previous research showing that bringing down iron may be a path to new treatments.
"An accumulation of iron in neurons seems to be a final end-stage event in neurodegeneration, whether it be Alzheimer's or Parkinson's, [or] any [condition] related to tau abnormalities," says Dr. Bush, who is also a fellow at the university's Mental Health Research Institute.
Other proteins affected in Alzheimer's also play a role in metal regulation. The amyloid precursor protein is important in helping export iron from the brain, according to work published in the journal Cell in 2010. Presenilin, another protein that aids in metal uptake, is also disturbed in diseased brains, according to a study published in Journal of Biological Chemistry last year.
Similar findings link copper accumulation and brain disease, though not as much research has been conducted as with iron, scientists say.
In addition to iron accrual, lower-than-normal levels of zinc have been found in patients with Alzheimer's and Parkinson's disease, according to work by George Brewer, an emeritus professor at the University of Michigan, and Edward Fitzgerald at the University at Albany-SUNY, published last year in the American Journal of Alzheimer's Disease and Other Dementias. Dr. Brewer now is a consultant to Adeona Pharmaceuticals Inc., based in Ann Arbor, Mich., which is developing a zinc-based treatment for Alzheimer's, he says.
Besides Adeona, a handful of other biotechnology companies have also been testing experimental metal-lowering drugs for treatment of Alzheimer's or Parkinson's. But developing such drugs is tricky because it is hard to target metals in specific parts of the brain. Simply lowering or increasing the amount overall in the body may not be beneficial, researchers say.
Metals may play a vital role in other brain conditions.
Stephen Lippard, a chemistry professor at the Massachusetts Institute of Technology, and colleagues from Duke University and the University of Toronto, found zinc helps neurons communicate in the hippocampus, a brain region involved in learning and memory. Disturbing this interaction, or ushering zinc into a brain region where it doesn't belong, could affect memory formation and the occurrence of epileptic seizures, says Dr. Lippard, who studies the role of metal ions in biology, neuroscience, and medicine. Their work was published in September in Neuron.
"It's important that the medical community continue to be alerted to the connection between metal ions and neurological disease," says Dr. Lippard.
Dr. Connor and his Penn State team have shown that patients with ALS have a higher rate of mutation in a gene, HFE, that regulates iron absorption. Carriers of the mutation have higher levels of iron in the brain and a fourfold increase in risk of ALS, according to a 2004 study published in the Journal of Neurological Sciences.
They have also been trying to figure out why the patients with multiple sclerosis lose the protective coating, called myelin, surrounding their axons, the part of the nerve cell that conducts electrical impulses. The cells responsible for making the myelin have elevated iron, making them more vulnerable to damage and death, says Dr. Connor.
Metals, Positive and Negative
Several metals play vital roles in the human body, but diseases can disturb their balance, causing harm.
Iron
Normal function: Involved in oxygen transport; needed to make energy for cells.
In the brain: Excess levels of iron are linked to Alzheimer's and Parkinson's diseases. Proteins and mutations related to iron delivery or absorption appear to be connected to Lou Gehrig's disease and multiple sclerosis.
Copper
Normal function: Helps transport oxygen, often works in tandem with iron.
In the brain: Wilson disease stops the body from getting rid of copper, which can cause speech problems, tremors and muscle stiffness. Disruption in copper regulation causes Menkes disease, which leads to abnormally low copper levels.
Zinc
Normal function: Helps make DNA and RNA, regulates cell death, and plays a role in short-term memory and learning.
In the brain: Low levels or the presence of the metal in areas of the brain where it isn't normally found are thought to impair memory.
—Source: WSJ reporting
Write to Shirley S. Wang at shirley.wang@wsj.com
Thanks for the info ... I've been waiting for a long time to see what's going to happen afterwards.
New insider buying is terrific news. I like the confidence.
Google "3D Laparoscopic Surgery" and you'll find there are very few results ... Viking is on the technology doorstep with few competitors.
Thier equipment is being sold, and when we least expect it, "3D" is going to go from being relatively unknown to the common place way surgery is performed.
Here is an article from March 2, 2011 about "The UK’s first 3D laparoscopic surgery".
http://3dlaparoscopicsurgery.com/?paged=4
Laparoscopic surgery is patient friendly. It's not going away.
Note the 2nd disadvantage below ... Viking's 3-D eliminates the problem!
Advantages
There are a number of advantages to the patient with laparoscopic surgery versus an open procedure. These include:
*Reduced hemorrhaging, which reduces the chance of needing a blood transfusion.
*Smaller incision, which reduces pain and shortens recovery time, as well as resulting in less post-operative scarring.
*Less pain, leading to less pain medication needed.
*Although procedure times are usually slightly longer, hospital stay is less, and often with a same day discharge which leads to a faster return to everyday living.
*Reduced exposure of internal organs to possible external contaminants thereby reduced risk of acquiring infections.
Disadvantages
While laparoscopic surgery is clearly advantageous in terms of patient outcomes, the procedure is more difficult from the surgeon's perspective when compared to traditional, open surgery:
*The surgeon has limited range of motion at the surgical site resulting in a loss of dexterity
*Poor depth perception
*Surgeons must use tools to interact with tissue rather than manipulate it directly with their hands. This results in an inability to accurately judge how much force is being applied to tissue as well as a risk of damaging tissue by applying more force than necessary. This limitation also reduces tactile sensation, making it more difficult for the surgeon to feel tissue (sometimes an important diagnostic tool, such as when palpating for tumors) and making delicate operations such as tying sutures more difficult.
*The tool endpoints move in the opposite direction to the surgeon's hands due to the pivot point, making laparoscopic surgery a non-intuitive motor skill that is difficult to learn.
I bought more last week and today.
761 trades of mostly small share numbers.
I like the broad support this under the radar shipping company is attracting.
Very odd and un-natural trading yesterday and today.
SBLK Dividend = 5¢ paid quarterly (20¢ annually)
It looks like it's going to continue considering they implimented a share buy-back program so they are "saying to all who are listening" that they are financially strong.
SBLK Dividend = 5¢ paid quarterly (20¢ annually)
It looks like it's going to continue considering they implimented a share buy-back program so they are "saying to all who are listening" that they are financially strong.
SBLK Dividend = 5¢ paid quarterly (20¢ annually)
It looks like it's going to continue considering they implimented a share buy-back program so they are "saying to all who are listening" that they are financially strong.